Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

Financial Information

SCOLR Pharma, Inc.

BALANCE SHEET

June 30, December 31,

2008 2007

(Unaudited)

ASSETS

Current Assets

Cash and cash equivalents $8,024,052 $11,825,371

Accounts receivable 276,848 225,900

Interest and other receivables 1,295 16

Prepaid expenses and other assets 576,176 432,213

Total current assets 8,878,371 12,474,500

Property and Equipment - net of accumulated

depreciation of $1,132,711 and

$964,738, respectively 580,958 748,931

Intangible assets - net of accumulated

amortization of $422,087 and

$385,452, respectively 515,663 464,023

Restricted cash 564,000 -

$10,538,992 $13,687,454

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

Accounts payable $230,320 $757,420

Accrued expenses 454,956 586,849

Deferred gain - lease termination 1,000,000 -

Current portion of term loan 83,858 80,047

Total current liabilities 1,769,134 1,424,316

Long-term portion of term loa
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion ... consulting for global corporations operating in highly regulated ... its first annual Global User Group Conference, Xybion ... Philadelphia, Pennsylvania at the ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... novel combination of microscopy and data processing has given ... Laboratory an unprecedented look at the surface of a ... , The research team led by ORNL,s Zheng ... perovskite manganite, a complex material that exhibits dramatic magnetic ... behavior could benefit researchers who are interested in using ...
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... CBI is pleased to announce the full agenda for ... Access Congress, being held December 6-7, 2011 in Philadelphia, ... Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic ... Anchored by conference chairman, Robert Besthof, Vice President, ...
... -- Third ocular product partnered with Sanofi approved ... plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the ... Food and Drug Administration (FDA) has approved its Investigational ... development of UshStat ® , a novel gene-based treatment ...
... TRIANGLE PARK, N.C., Oct. 17, 2011 Max Neeman ... hemophilia trials according to the Clinical Trials Registry-India (CTRI). ... India, Max Neeman can boast supporting 80% of these ... International has established a team of experts specialized in ...
Cached Biology Technology:Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 3Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 4CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India 2
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
(Date:7/24/2014)... The planet,s current biodiversity, the product of 3.5 billion ... in the history of life. But it may be ... of scientific literature and analysis of data published in ... that the loss and decline of animals is contributing ... the planet,s sixth mass biological extinction event. , Since ...
(Date:7/24/2014)... terroir, meaning the microbial populations found on surfaces in ... the final flavor according to research published ahead of ... . This is the first time investigators have taken ... Many sake makers inoculate with both bacteria and yeast, ... of California, Davis, but he and his colleagues investigated ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2
... the University of Georgia, using glow-in-the-dark proteins and ... of a complex organelle in the bacterium that ... in new, precise detail the unique cell extension ... Mycoplasma pneumoniae. This structure, called a "terminal organelle," ...
... fruit flies, developmental biologists at the Kimmel Cancer Center ... a new way that genes are turned on and ... processes are at work in higher organisms, including mammals, ... understanding of a range of diseases, including childhood cancer. ...
... prevents the production of a critical blood-clotting protein. Treatments ... exist, may consist of risky blood transfusions or expensive ... be induced to begin producing these proteins, say by ... , Prof. Yair Reisner and Ph.D. student Anna Aronovich ...
Cached Biology News:UGA scientists unravel 'molecular inch-worm' structure of walking-pneumonia bacterium 2Jefferson researchers uncover new way nature turns genes on and off 2A transplant in time 2
CQCS kit for etra KR 4i , (other units)....
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
...
Biology Products: